Sun Pharma to acquire US-based Concert Pharmaceuticals for $576 million

Deal size could expand to $827 mn if additional milestone-based payments are made

Premium

The transaction is expected to be completed in the first quarter of 2023

Sohini Das Mumbai
 
India’s largest drugmaker by market share in the domestic pharmaceutical (pharma) market has stepped up its game in the US dermatology space with the acquisition of Concert Pharmaceuticals, Inc. (Concert), a Nasdaq-listed firm, for $576 million.
 
Concert is a biotechnology firm with an extensive patent portfolio. Its lead product candidate is deuruxolitinib, an oral drug for the treatment of alopecia areata, an autoimmune dermatological disease in late-stage development.
 
The deal size could expand up to $827 million (roughly Rs 6,800 crore) if the additional milestone-based payments are made.
 
Sun Pharmaceutical Industries (Sun Pharma) informed stock exchanges after market hours on Thursday that it

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 19 2023 | 8:02 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com